SEC 13F Intelligence

Managers / Q3 2022 · view latest →

Gates Foundation

CIK 0001663801 · 500 5TH AVE NORTH, SEATTLE, WA, 98109 · 206-709-3100

Reported Value
$127M
Q3 2022
Positions
10
Filings on Record
19
2019–present window
Filed
Nov 14, 2022
original filing

Summary

Gates Foundation reported $127M in U.S.-listed holdings across 10 positions for Q3 2022.

The portfolio is heavily concentrated: VIR alone accounts for 23.8% of reported value.

Compared with Q2 2022, the fund opened 1 new position and exited 0.

Portfolio Metrics

Turnover
+17.5%
vs prior filed quarter
Top-10 Concentration
+100.0%
share of reported value
Largest Position
+23.8%
Vir Biotechnology

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $438MQ4 ’20Q1 ’21: $656MQ2 ’21: $692MQ2 ’21Q3 ’21: $342MQ4 ’21: $330MQ4 ’21Q1 ’22: $186MQ2 ’22: $130MQ2 ’22Q3 ’22: $127MQ4 ’22: $130MQ4 ’22Q1 ’23: $113MQ2 ’23: $126MQ2 ’23Q3 ’23: $84MQ4 ’23: $90MQ4 ’23Q1 ’24: $84MQ2 ’24: $60MQ2 ’24Q3 ’24: $44Mfilingsflow.com

Portfolio Composition

By security type
ADR: 47.7%Common Stock: 30.1%Other: 22.2%
  • ADR · 47.7% · $60M
  • Common Stock · 30.1% · $38M
  • Other · 22.2% · $28M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2022 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
LUMIRADX LTDNEW+14.29M14.29M+$15M$15M
ATRECA INCHELD10.5K1.32M$300,000$2M
CUREVAC N VHELD+01.71M$10M$14M
VIRVIR BIOTECHNOLOGY INCHELD+01.56M$10M$30M
IMCRIMMUNCORE HLDGS PLCHELD+0576.9K+$6M$27M
EXSCIENTIAHELD+01.59M$4M$13M
BNTXBIONTECH SEHELD+0148.7K$2M$20M
BFLYBUTTERFLY NETWORK INCHELD+01.01M+$2M$5M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2022

10 positions
#IssuerClass% PortfolioValueShares
1VIRVIR BIOTECHNOLOGY INChistory →COM23.79%$30M1.56M
2IMCRIMMUNCORE HLDGS PLChistory →ADS21.42%$27M576.9K
3BNTXBIONTECH SEhistory →SPONSORED ADS15.89%$20M148.7K
4LUMIRADX LTDSHS11.54%$15M14.29M
5CUREVAC N VCOM10.67%$14M1.71M
6EXSCIENTIAADS10.36%$13M1.59M
7BFLYBUTTERFLY NETWORK INChistory →CL A COM3.79%$5M1.01M
8ATRECA INCCL A COM1.66%$2M1.32M
9AMYRIS INCCOM NEW0.71%$900,000292.4K
10ZYUSDZYMERGEN INCCOM0.16%$200,00060.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2024$44M5Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$60M6Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$84M8May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$90M8Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$84M9Nov 13, 202313F-HRchanges · EDGAR ↗
Q2 2023$126M9Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$113M9May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$130M9Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$127M10Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$130M9Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$186M11May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$330M11Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$342M10Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$692M8Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$656M7May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$438M5Feb 16, 202113F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.